A Forward Look, the Year Ahead -- Featured Research on Achillion Pharmaceuticals, Inc. and Nektar Therapeutics
HONG KONG -- (Marketwire) -- 01/13/12 -- Today, www.BollingerReport.com introduced featured coverage of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) and Nektar Therapeutics (NASDAQ: NKTR). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=ACHN&sm2=NKTR.
Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.
Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.
Bollinger Report screened and selected Achillion Pharmaceuticals, Inc. for its current position within the healthcare industry. Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. A copy of this report featuring Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is available at: www.BollingerReport.com/index.php?sm1=ACHN.
Bollinger Report is featuring Nektar Therapeutics for its changing role within the healthcare industry. Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The Company's product pipeline consists of drug candidates across a range of therapeutic areas, including oncology and pain. To download researches and analysis on Nektar Therapeutics (NASDAQ: NKTR) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=NKTR.
About Bollinger Report
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here